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enrolled into the ACOS-Registry (Acute Coronary Syndrome, 154 hospitals) in Germany. 
We analysed the prospective data of STEMI-pts with special respect to the smoking sta- 
tus. 
Results: Out of 5122 consecutive pts with STEMI. 1852 (36%) were current smokers 
and 2753 (54%) had never smoked (nonsmokers). Smokers were at mean 15 years 
younger, more often male and had less often hypertension and diabetes as additional 
cardiovascular risk factors. Smokers did receive acute repelfusion therapy more often. 
The hospital mortality in nonsmokers was three times higher than in smokers. After cor- 
recting for differences in baseline characteristics and acute repedusion and adjunctive 
therapy rn a multivariate analysis smoking did not influence hospital mortality after 
STEMI (OR 0.80. 95% Cl 0.60-1.06). 
Conclusion: In smokers STEMI occurred 15 years earlier in age than in nonsmokers. In 
a multivariate analysis smoking did not influence the outcome of STEMI. 
Parameter 
Age (years) 
Male gender 
Prior MI 
Hypercholesteremia 
Hypertension 
Diabetes 
CK max (U/l) 
Acute Repedusion 
Thrombolysis 
Primary PCI 
Hospital Modality 
Smokers 
n=l852 
56 
81 .6 % 
6.4 % 
47.4 % 
45.0 % 
16.1 % 
625 
78.7 % 
26.7 % 
52.0 % 
4.7 % 
Nonsmokers 
n=2753 
71 
60.4 % 
12.8% 
40.2 % 
63.3 % 
30.5 % 
532 
64.6 % 
20.7 % 
44.1 % 
13.3 % 
p-value 
co.01 
<O.Ol 
<O.Ol 
<O.Ol 
<O.Ol 
co.01 
<O.Ol 
co.01 
<O.Ol 
<O.Ol 
co.01 
Et:45 a.m. 
869-2 Comparison of the Importance of Increasing Pathogen 
Burden, Elevated C-Reactive Protein, and the Presence 
of Antibodies to Heat Shock Protein 60 on Myocardial 
Infarction or Death 
Jianhui Zhq Stephen E. Epstein, Joseph B. Muhlestein, Javier F. Nreto, Amy 
Wasserman, Benjamin D. Home, David Rott, Jeffrey L. Anderson, Washington Hospital 
Center, Washington, DC, LDS Hospital, Salt Lake City, UT 
In addition to the importance of traditional risk factors, recent evidence suggests that 
infectious pathogens, C-reactive protein (CRP) and heat shock protein (HSP) play roles 
in the progression of atherosclerosis and can be used as outcome predictors. In the 
present study, we compared the relative importance of a) pathogen burden (seropositiv- 
iky to cytomegalovirus, hepatitis A virus, C. pneumoniae, H. pylori, herpes simplex virus 
type 1 and type 2) b) CRP levels, and c) anti-human HSPGO antibodies in predicting 
myocardial infarction (MI) or death. The patient cohorl consisted of 890 patients (77% 
men. mean age 65 years) with coronary artery disease (CAD) documented by coronary 
angiography (2 70% stenosis). The mean follow-up period was 3 years. By both univari- 
ate and Cox multivariate regression analyses, pathogen burden and elevated CRP levels 
were strong and independent predictors of incident Ml or death. The highest relative haz- 
ard was conveyed by pathogen burden (Table 1). In contrast, HSPGO antibodies were not 
significant determinants of MI or death. We conclude that in patients with documented 
CAD, both pathogen burden and elevated CRP levels are important independent predic- 
tors of MI or death, suggesting that infection and inflammation contribute to the disease 
processes leading lo acute coronary occlusion. Although HSPGO has been associated 
with angiographic evidence of the presence and extent of CAD, it’s role in the acute com- 
plications of CAD is still to be determined. 
Table 1. Comparison of Relative Hazard (95%CL) of Incident MI or Death 
Pathogen BurdenO-3 
4 
5 
6 
CRP Tadile 1 
2 
3 
HSPGO Ab (c) 
HSPGO Ab (-) 
Unadjusted Adjusted For CAD Risk Factors 
1 .o 
1.9 (0.6-4.4) 
3.2 (I .4-6.9) 
4.6 (2.1-9.9) 
1 .o 
1.9 (1.3-2.9) 
1 .Q (1.3-2.9) 
1.0 
1.2 (0.8-I .6) 
1 .o 
1.5 (0.6-3.5) 
2.6 (I .2-5.7) 
3.1 (1.4-6.8) 
1.0 
1.8 (I .2-2.6) 
1.7 (1.1-2.5) 
1.0 
1.2 (0.8-l .6) 
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869-3 Increased Concentrations of Bone Marrow-Derived 
Stem Cells in Peripheral Blood After Acute Myocardial 
Infarction 
Antonio Maria Leone, Sergio Rutella. Felicita Andreotti, Luca Pierelli, Mariaelena 
Lombardi, Giuseppe Leone, Filippo Crea, Universita Cattolica del Sacro Cuore, Rome, 
Italy 
Background: recent studies in expenmental models have shown that bone marrow- 
derived stem cells (BMSCs) can regenerate myocardial tissue after a myocardial infarc- 
tion. Moreover, the presence of cardiomyocytes of extracardiac origin has been reported 
in human transplanted heads. It is reasonable to assume, therefore, that EMSCs may be 
released into the peripheral blood after an acute myocardial infarctron (AMI). migrate 
towards the head, and there differentiate into cardiomyocytes to repas, at least in part, 
the damaged tissue. The awn of this study was to evaluate whether BMSC concentra- 
tions increase in peripheral blood after an AMI. Methods: BMSC concentratrons were 
measured by flow-Cytometry as CD34+ cellslmicroliter (mcl) rn the peripheral blood of 22 
patients with AMI after I, 3, 5 and 7 days from the event and in 11 healthy controls with- 
out cardiovascular risk factors of similar age, sex and race. Results In agreement with 
the literature, the median concentration of CD34+ cells in healthy controls was <l/mcl 
(0.47/mcl, interquartile range - IR - 0 to 0.94). In contrast, in the absence of clinical and 
laboratory findings of hemoconcentration, the median concentration of CD34+ cells in 
patients with AMI was significantly increased at 1, 3, 5 and 7 days from the event to 4.461 
mcl (IR 2.6 to 8.4, p=O.OOOS), 2.9l/mcl (IR 2.16 to 4.045, p=O.O014), 5.03imcl (IR 2.36 to 
7.9, p=O.O013). and 7.925 (IR 5.26 to 12.68, p=O.O075), respectively (Figure). Conclu- 
sions: In patients with AMI there is an increase in peripheral bone marrow-derived stem 
cell concentrations. These results support the hypothesis that these cells may migrate, 
differentiate, proliferate and contribute to remodel the infarcted myocardium. 
9:15 a.m. 
869-4 Association of Left Ventricular Hypertrophy Regression 
and Heart Rate Reduction With Determinants of 
Myocardial Oxygen Consumption and Cardiovascular 
Events: The LIFE Study 
Richard B. Devereux, Kristian Wachtell, Eva Gerdts. Peter Aurup, Kurt Boman, Jonathan 
Edelman, Markku Nieminen, Vasilios Papademetriou, Ying Wan, Bjorn Dahlof. Steve 
Julius, Weill Cornell Medical Center, New York, NY 
Background: Expenmental studies have demonstrated that increased myocardral 02 
consumption demand due to left ventricular hypedrophy (LVH) increases the likekhood 
and size of myocardial infarction (Ml) with a standardized coronary occulusion, but no 
human data exist to separate the potentially beneficial effects of LVH regression and 
reduced myocardial 02 demand on the rate of Ml in treated hypertensive patients. Meth- 
ods: In a double-blind, randomized, parallel-group design 960 participants in the Losar- 
tan Intervention for Endpoint reduction in hypertension (LIFE) study (average age 66 
years, blood pressure 174198 mmHg) and ECG-documented LVH were assigned once 
daily losartan- or atenolol-based therapy and underwent echocardiography after 1.2.3,4 
and 5 years’ treatment. LV mass and the LV mass x end-systolic stress x heart rate triple 
product were measured as indices of LVH and 02 demand. Results: Blood pressure was 
reduced similarly in the two treatment arms (mean=-29.7116.2 versus -2&O/16.0 mmHg, 
NS) but heart rate fell more on atenolol (meafw7.2 versus -1.1 beats per minute, 
p<O.OOl). LV mass was reduced more in losartan than atenolol-treated patrents (mean=- 
22.0 versus -17.7 glm2, p=O.O21). In contrast, the triple product fell more on atenolol- 
based therapy (mean=-28% versus -18% p<O.OOl). In Cox regressions adjusting for 
treatment, baseline LV mass index and baseline and in-treatment pressures, each 25 g/ 
m2 lower LV mass index was associated with risk reductions (95% Cl) of 22 (5-34, 
p=O.O2)% for stroke and 33 (17-43, p=O.OOl)% for cardiovascular (CV) mortality but only 
13 (33 t0 -17, NS)% for Ml. Conclusion: Losartan-based antrhypertensive therapy 
reduced LV mass more but atenolol reduced the triple product (index of myocardial 02 
demand) by 10% more, potentially contributing to less reduction in Ml than stroke or CV 
death associated with reduction of LV mass and to less effect of losartan than atenolol on 
MI than stroke or CV death in the enhre LIFE study. 
9:30 a.m. 
869-5 The Assessment of Myocardial Viability With Delayed 
Contrast Enhancement Using Computed Tomography 
Aaron So Jennifer Hadway, Jane Sykes, Gerald Wisenberg, Frank Prato, Tin-S” Pan, -3 
Ting-Yim Lee, Lawson Health Research Institute and Robarts Research Institute, 
London, ON, Canada, General Electric Medical Systems, Waukesha, WI 
Background: Delayed enhancement of contrast has emerged as the most popular MRI 
approach to detect ischemic injury to myocardium. We have developed a CT technique 
for the quantitative measurement of myocardial distribution volume (MDV) of contrast 
media using retrospective ECG gated tine scanning. 
Methods: Four 15-25 kg beagles were used for the study. For MDV measurement, a 30 
s baseline (without contrast) tine scan was performed in synchrony with ECG recording 
using a General Electric Medical Systems (GEMS) Lightspeed multi-slice CT scanner. 
Contrast (Omnipaque, 225 mgllml) was then constantly infused for 30-60 min before the 
scan was repeated. Images were reconstructed with half-scan data (330 ms) at 0.1 S 
interval and those at end-diastole (ED) were selected with SmartScore (GEMS) and 
averaged with CT Perfusion 2 (GEMS). MDV maps were generated by subtracting the 
averaged non-contrast enhanced ED images from the corresponding averaged constant 
infusion images. The difference images were normalized to the enhancement in the 
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aorta. Baseline measurements of MDV were obiamed on each beagle prior to 2 hours 
occlusion of the left anterior descending arlery (LAD) and then repeated at 4 hours reper- 
fusion and also at day 4, 9, 16, 23 and 30 post. At day 30 post, the heart was removed 
following MDV measurement and scanned ex-viva at high spatial resolutmn before it was 
sliced and stained with TTC. 
vs. 3.4%. P=O.14), while it was asswated with death at one year (12.2% vs. 7.2%. odds 
ratio = 1.78, 95% Cl 1.41 to 2.26, P < O.OOOl). There was increased risk of death with 
increasing Cornell voltage, especially in women. (Figure) 
Results: MDV in the apical region of the heart Increased from a mean baseline value of 
0.4 f 0.1 ml/g to 0.9 * 0.05 ml/g immediately after reperfusion and remained above 0.6 
ml/g until day 4 post. From day 9 post MDV normalized except for a thin subendocardial 
rim in the apical region. High resolution ex-viva scan of the removed heart confirmed the 
location of the rim enhancement seen in the MDV image to be subendocardial. TTC 
staining further confirmed that the rim enhancement was infarcted tissue. MDV in normal 
myocardium at the lateral free wall of the left ventricle was 0.4 * 0.05 mlJg at all time 
points. 
Female 
Conclusion: We concluded from our preliminary results that ECG- gated contrast- 
enhanced CT scanning is a promising and simple approach for studying myocardial dam- 
age from &hernia and its resolution with time. 
9:45 a.m. 
869-6 Can Anatomic No-Reflow Be Prevented by 
Pharmacologic Treatment With Adenosine and 
Verapamil? 
Thor&n Reffelmann, Robert A. Kloner, The Heart Institute. Good Samaritan Hospital, 
University of Southern California, Los Angeles, CA 
Objectives: The aim was to Investigate the effects of intravenous adenosine and vera- 
pamil on anatomic no-reflow (ANR) in a rabbit model of coronary artery occlusion and 
reperfusion. 
Background: Verapamil and adenosine have been successfully used in treatment of 
clinical no-reflow after direct angioplasty for acute myocardial infarction. However, 
whether these agents reduce anatomic no-reflow associated with myocardial necrosis, 
as It occurs in animal models of coronary occlusion and repertusion, is unknown. 
Methods: ANR (thioflavin S at end of reperfusion), regional myocardlal blood flow 
(RMBF. radioactive mlcrospheres), and infarct size (IS, triphsnyltetrazolium) were com- 
pared in anesthetized, open-chest rabbits (&hernia-reperfusion: 30-120 minutes) receiv- 
ing intravenous adenosine at reperfusion (875 vglkg b&s, then 175 pglkglmin until the 
end of reperfusion) against controls (saline) (n=6, each), and rabbits treated with intrave- 
news verapamll at reperfusion (50 pglkg bolus, then 150 vg/kg/h) against saline (n=6. 
each). 
Results: Both regimes significantly lowered systolic and diastokc blood pressure. 
reduced specific vascular resistance in the risk area (RA)(adenosine: -38.7% and -38.7% 
at 30 and 120 min of reperfusion, verapamil: -52.5% and -54.3% at 30 and 120 min of 
reperiusion), and verapamil increased RMBF within the risk area (verapamil: 4&7%. 
saline: 33*5% of non-ischemic flow at 120 min of reperfusion). IS (adenosme: 
34.1*4.3%, saline: 39.6+6.2% of RA) and ANR (adenosine: 26.8*3.2%, saline: 
35.2*5.8% of RA) were not significantly different in the adenosine protocol, and signih- 
cantly correlated with each other (r=0.96). Similarly, verapamil did not result in significant 
effects on IS (verapamil: 42.2+5.9%. salme~ 36+6.3% of RAI. and ANR iveraoamll: 
37.6+5.5%. saline’ 34.9r5.7% of RA), which again showed a significant correlation 
h&96). ANCOVA analvsis revealed that neither treatment uncouoled ANR from IS. 
Conclusion: Despite reducing vascular resistance within the RA, both adenosine and 
verapamll at reperfus~on did not reduce ANR, suggesting that vasospasm is not a major 
contributor to anatomic perfusion defects in this experimental model. 
ORAL CONTRIBUTIONS 
872 The Old and the New: The ECG and Novel 
Biomarkers in Acute Coronary 
Syndromes 
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8:30 a.m. 
872-l Does the Presence of Electrocardiographic Left 
Ventricular Hypertrophy Predict One-Year Mortality in 
Non-ST Elevation Acute Coronary Syndromes? 
Michael S. Lauer, Yuling Fu, Wei-Ching Chang, Robert M. Califf, Maarten Simoons, Lars 
Wallentin, Eric J. Topol. Paul W. Armstrong, Cleveland Clinic Foundation, Cleveland, 
OH, University of Alberta, Edmonton, Canada 
Background: Whereas electrocardiographic (ECG) left ventricular hypertrophy (LVH) 
predicts long-term mortality in otherwise healthy people, its importance as a predictor of 
death in the setting of NSTEMI acute coronary syndromes (ACS) is not known. 
Methods: Patients wth ACS who were enrolled in the GUSTO IV randomized trial had 
baseline ECGs read in a blinded core laboratory. LV mass was assessed by Cornell volt- 
age, which is the sum of the amplitude of the S wave in V3 and the R wave in lead Vl. 
LVH was defined as a voltage? 26 mm in men and 220 mm in women. 
Results: Baseline ECG data were available in 7443 (95%) of 7800 patients enrolled. 
ECG LVH was present in 747 patients (10%). During follow-up, 260 patients (3.5%) died 
by 30 days and 574 (7.7%) by 1 year. ECG LVH tended to predict death at 30 days (4.4% 
After adjusting for age, ST-segment depression, troponin, C reactive protein, and other 
confounders using logistic regression, Cornell voltage remained independently predictive 
of l-year mortality (p=O.OlE), but only in women (p&O31 for the interaction between 
Cornell voltage and sex; I” gender specific analyses, p=O.O05 and 0.339 for Cornell volt- 
age in women and men, respectively). 
Conclusion: EGG LVH at baseline is an independent predictor of lyear mortality among 
women presenting with ACS. 
8:45 a.m. 
872-2 The Prognostic Value of ST-Segment Elevation in Lead 
AVR in Patients With a First Acute Myocardial Infarction 
Without Other ST Elevation 
Jose A. BarrabBe Jaume Figueras, Cristina Moure, Josefa Cortadellas, Jordi Soler- 
Sole,, Hospital Universitari Vail d’Hebron. Barcelona, Spain 
Background: ST segment elevation (STE) in lead aVR has been associated with severe 
coronary lesions in patients with acute coronary syndromes, but the prognostic signifi- 
cance of this finding is unknown. 
Methods: We analyzed the initial EGG in 775 consecutive patients admitted to ~urcenter 
with a first acute myocardial infarction without STE in leads other than aVR. 
Results: Compared to the remaining patients, those with STE in lead aVR had a higher 
baseline risk profile and a more frequent and extensive ST segment depression in other 
leads. The rates of death and other in-hospital complications were strongly associated 
with the magmtude of STE in lead aVR, while CK-MB levels were not (Table). After 
adjustment for age, Killip class and presence and location of ST segment depression, the 
odds ratios for death in the last two groups shown in the table were, respectively, 5.6 
(95% confidence interval, 2.0-15.5) and 7.6 (3.1-19.9). Among 437 patients catheterized 
within SIX months, those wth STE in lead aVR had a lower left ventricular ejection frac- 
tion and a more extensive coronary artery disease. 
Conclusion: Lead aVR contains important prognostic information in patients with a first 
acute myocardial infarction without other STE. As the wrse wtcome predicted by STE 
in lead aVR appears to be related to a more s?vera coronary artery disease, an early 
invasive approach might be especially beneficial in these patients. 
Death, % 
Reinfarction, % 
Angina, % 
Heart failure, % 
CK-MB peak, IU/I 
No STE in 
lead aVR 
(n=525) 
1.3 
2.1 
10.3 
3.2 
127i.103 
Len ventricular ejection 66t12 
fraction, % 
Len main or three 22.0 
vessel disease, % 
STE 0.05-0.1 mV 
in lead aVR 
(n=116) 
8.6 
6.0 
19.8 
10.3 
126*102 
63+11 
42.6 
STE z-=0.1 mV in P 
lead aVR valu 
(n=134) e 
19.4 co.0 
01 
6.0 0.00 
9 
26.9 co.0 
01 
30.6 <o.o 
01 
119*95 NS 
59+16 <o.o 
01 
66.3 <o.o 
01 
